|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
German Clinical Trials Register |
|
Last refreshed on:
|
8 April 2024 |
|
Main ID: |
DRKS00011339 |
|
Date of registration:
|
02/12/2016 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
„Caroline meets HANNA – Holistic Analysis of LoNgterm-survival with OvariaN CAncer”
Expression VI
|
|
Scientific title:
|
„Caroline meets HANNA – Holistic Analysis of LoNgterm-survival with OvariaN CAncer”
Expression VI - Expression VI |
|
Date of first enrolment:
|
15/11/2016 |
|
Target sample size:
|
300 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://drks.de/search/en/trial/DRKS00011339 |
|
Study type:
|
observational |
|
Study design:
|
Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Austria
|
Belgium
|
Czechia
|
Germany
|
Hungary
|
Italy
|
Lebanon
|
Poland
|
|
Romania
|
Slovakia
|
Slovenia
|
Spain
|
Switzerland
|
Turkey
|
Ukraine
| |
|
Contacts
|
|
Name:
|
|
|
Address:
|
Augustenburger Platz 1
13353
Berlin
Germany |
|
Telephone:
|
0049 30 664 458 |
|
Email:
|
carolin-meets-hanna@charite.de |
|
Affiliation:
|
Charité Universitätsmedizin Berlin |
|
|
Name:
|
Hannah
Woopen |
|
Address:
|
Augustenburger Platz 1
13353
Berlin
Germany |
|
Telephone:
|
0049 30 664 458 |
|
Email:
|
hannah.woopen@charite.de |
|
Affiliation:
|
Charité Universitätsmedizin Berlin |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: - initial diagnosis at least five years ago
- ovarian, peritoneal or fallopian tube cancer
Exclusion criteria: - Other gynaecological tumours
Age minimum:
18 Years
Age maximum:
None
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
C56
C48
C57
|
|
Malignant neoplasm of ovary
|
|
Malignant neoplasm of retroperitoneum and peritoneum
|
|
Malignant neoplasm of other and unspecified female genital organs
|
|
Intervention(s)
|
Group 1: Questionnaire with 68 questions regarding
- basic data (age at diagnosis, co-medication, comorbidities, tumor stage, treatment)
- side effects, follow on treatment, aftercare, participation in studies
- social factors
- psycologic factors (resilience, coping)
- quality of life
- nutrition, religion, sports, sleep
|
|
Primary Outcome(s)
|
|
Identification of factors for long term survival
|
|
Source(s) of Monetary Support
|
|
Stiftung Eierstockkrebs
|
|
AstraZeneca
|
|
Ethics review
|
Status: Approved
Approval date: 12/08/2016
Contact:
ethikkommission@charite.de
Ethikkommission der Charité – Universitätsmedizin Berlin
(+49)30-450517222
ethikkommission@charite.de
|
|